Kymera Therapeutics, Inc.
KYMR
$117.39
$2.972.60%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 466.40% | 55.50% | -61.18% | -26.12% | -55.26% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 466.40% | 55.50% | -61.18% | -26.12% | -55.26% |
| Cost of Revenue | 52.42% | 22.31% | 16.73% | 22.65% | 32.41% |
| Gross Profit | 18.58% | -9.70% | -25.67% | -25.87% | -99.43% |
| SG&A Expenses | 19.73% | 25.11% | 3.69% | 12.17% | 1.57% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 46.42% | 22.78% | 14.31% | 20.52% | 25.41% |
| Operating Income | 10.58% | -13.07% | -21.23% | -22.94% | -66.04% |
| Income Before Tax | 20.10% | -5.57% | -22.94% | -31.51% | -82.15% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 20.10% | -5.57% | -22.94% | -31.51% | -82.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 20.10% | -5.57% | -22.94% | -31.51% | -82.15% |
| EBIT | 10.58% | -13.07% | -21.23% | -22.94% | -66.04% |
| EBITDA | 10.46% | -13.48% | -21.57% | -23.77% | -67.06% |
| EPS Basic | 34.53% | 13.26% | -9.37% | -14.68% | -65.42% |
| Normalized Basic EPS | 34.53% | 13.24% | -9.37% | -9.30% | -65.43% |
| EPS Diluted | 34.53% | 13.26% | -9.37% | -14.68% | -65.42% |
| Normalized Diluted EPS | 34.53% | 13.24% | -9.37% | -9.30% | -65.43% |
| Average Basic Shares Outstanding | 22.04% | 21.70% | 12.41% | 14.68% | 10.12% |
| Average Diluted Shares Outstanding | 22.04% | 21.70% | 12.41% | 14.68% | 10.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |